Cartilage News and Research

RSS

Cartilage is a stiff yet flexible connective tissue found in many areas in the bodies of humans and other animals, including the joints between bones, the rib cage, the ear, the nose, the elbow, the knee, the ankle, the bronchial tubes and the intervertebral discs.

Viewing knee as an organ could lead to better therapies for treatment of osteoarthritis

The human body is made up of several organs composed of tissues that enable them to perform a particular function. The heart circulates blood; the brain is the micro-neuro center of the body; the lungs bring in oxygen and release carbon dioxide.

15 Feb 2011

Researchers identify enzyme that protects against inflammation, joint destruction

A team of researchers at the University of Gothenburg, Sweden, has identified an enzyme that protects against inflammation and joint destruction. Made when the researchers blocked production of the enzyme GGTase-I in transgenic mice, this unexpected discovery could lead to the identification of new mechanisms that control the development of inflammatory disorders, as well as new medicines.

8 Feb 2011

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office has granted the company a key patent covering the primary technology for ISTO's NuQu product.

7 Feb 2011

Blood vessels for heart bypass could be available ‘off-the-shelf’ soon: Study

Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient’s own cells, but this takes several months.

6 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.

3 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

FDA schedules panel meeting date for BioMimetic Therapeutics's Augment Bone Graft PMA

BioMimetic Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled an Orthopedic and Rehabilitation Devices Panel meeting on May 12, 2011 to review the Company's Premarket Approval (PMA) application for Augment™ Bone Graft for the treatment of foot and ankle fusions in the U.S.

1 Feb 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

Study shows physical activity helps people with osteoarthritis to walk faster

When a traffic light at a busy intersection flashes the WALK sign, people with knee osteoarthritis worry they can't walk fast enough to make it across the street in time. New Northwestern Medicine research shows people with this common arthritis are more likely to walk fast enough if they lead physically active lives.

19 Jan 2011

Biocordcell Argentina launches program to store dental pulp stem cells

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. (BioCells, Inc.) has launched a program to store dental pulp stem cells, the first stem cell storage bank in Argentina to offer this service.

13 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a Phase I clinical trial of its self-applied ViaDerm-Calcitonin product for the treatment of musculoskeletal disorders such as osteoarthritis and musculoskeletal pain.

11 Jan 2011

Skin cells for repairing cartilage injury

In this paper, Noriyuki Tsumaki and his team at the Osaka University Graduate School of Medicine, used fibroblasts isolated from adult mouse skin, and expressed proteins used to induce pluripotency along with a factor that promotes a chondrocyte fate.

11 Jan 2011

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Artificial joint replacements can drastically change a patient's quality of life. Painful, arthritic knees, shoulders and hips can be replaced with state-of-the-art metal or ceramic implants, eliminating pain and giving a person a new lease on life.

6 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011